Biochemistry

Mogrify Adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board – Business Wire

CAMBRIDGE, England--(BUSINESS WIRE)--Mogrify Ltd (Mogrify), a UK biotechnology company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, today announced the appointment of Lorenz Mayr, PhD, to the Board of Directors and the Scientific Advisory Board (SAB). Dr. Mayr will initially join the Board of Directors as an observer, providing valuable insights into the development and manufacture of ex vivo cell therapies and in vivo reprogramming therapies and advising on the Companys therapeutic program selections, before assuming full board member status later this year.

Dr. Mayr has over 30 years experience in biopharma research, development and commercialization. He joins the Mogrify Board having most recently been Chief Technical Officer at GE Healthcare Life Sciences, where he was responsible for all global R&D activities, talent development and company growth strategy across all business areas including cell therapy manufacturing. His previous industry roles include Vice President & Global Head at AstraZeneca, where he oversaw the generation of biological reagents and assay development activities across all therapeutic areas, and Executive Director at Novartis Pharma AG. He is a Biochemistry lecturer at the Martin Luther University Halle-Wittenberg and has published over 60 papers in peer-reviewed journals. He obtained his PhD in Biochemistry and Biophysics at the University of Bayreuth. Dr. Mayr currently serves as an Entrepreneur in Residence at Syncona Ltd.

Darrin M. Disley, PhD, CEO, Mogrify, said: We are excited to welcome Dr. Mayr to both the Board of Directors and the Scientific Advisory Board. His appointment further strengthens our senior team, which includes industry leaders in platform technologies, drug development and biotech company building. Lorenzs expansive knowledge of pre-clinical R&D, clinical drug development and manufacture and his global biotech and pharma network will be invaluable in our mission to transform the development of lifesaving therapies in disease areas including hematology, immunology and ophthalmology.

Lorenz Mayr, PhD, Board and SAB member, Mogrify, added: Mogrify has developed an innovative direct cellular conversion technology that has a great potential for diseases with a high unmet clinical need. The Company is well-positioned to address shortcomings in the cell therapy space as well as pioneer in vivo reprogramming therapies, and I am pleased to be joining at such an exciting stage in its growth. I am looking forward to working with a team with proven world-class scientific and commercial expertise.

For further information about Mogrifys team, please visit: http://www.mogrify.co.uk/board-of-directors

See the rest here:
Mogrify Adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board - Business Wire

Biochemistry

Global Biochemistry Analysers Market 2020 Industry Analysis, Key Drivers, Business Strategy, Opportunities and Forecast to 2025 – Red & Black…

Recently updated and published a report titled Global Biochemistry Analysers Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025, by Researchstore.biz highlights lubricants market growth potentials which can assist the stakeholders to understand key trends and prospects in the market as well as identify the growth opportunities and competitive scenarios. The report contains factors such as market size, market share, market segmentation, significant growth drivers, market competition, and diverse features affecting the global Biochemistry Analysers market. The report analyzes each segment in the global Biochemistry Analysers market. The report focuses on the markets growth potential, which can help investors identify scope and opportunities.

The report scrutinizes the market framework and based on that it presents a summary of policies and improvement plans. The report features premium quality data figures associated with financial figures of the industry like market size, sales data, and revenue figures through graphics, diagrams, charts, and numbers. These figures make the report more influential and easy to understand. The report recognizes the technical barriers, other issues, and cost-effectiveness affecting the market. It offers useful guidelines for players to secure a position of strength in the global Biochemistry Analysers market.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/40411

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Multi Channel Flame Photometers market.

Company Profiles:

Every market participant needs to be familiar with the competitive scenario in the global Biochemistry Analysers industry. In order to fulfill the requirements, the industry analysts have examined the strategic activities of the competitors to help the key players increase their competitiveness. The report studies the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production.

The major market players that are operating in the global Biochemistry Analysers market are Thermo Fisher Scientific , MicroLab Instruments , Siemens Healthcare , Abbott , RMS , HORIBA , Agappe Diagnostics , Xylem Analytics , Labindia Instruments . All these market players are profiled in the market report.

The study provides an in-depth overview of country-level break-up classified as potentially high growth rate territory, countries with the highest market share in past and current scenario. Some of the regional break-up classified in the study are: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East& Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Market segmentation by product: Fully Automated Biochemistry Analyser, Semi Automated Biochemistry Analyser

Market segmentation by application: Hospital and Diagnostic Laboratories, Home Care, Academic and Research Institutes

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-biochemistry-analysers-market-40411

The Following Doubts Are Addressed In The Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@researchstore.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@researchstore.bizWeb: http://www.researchstore.biz

You May Check Our Other Report

Global Arteriovenous (Av) Fistula Needle Market 2020 Forecast to 2025Global Glass Reuse Market 2020 Forecast to 2025Global Solvent Reuse Market 2020 Forecast to 2025Global 5G Network Infrastructure Market 2020 Forecast to 2025Global Photovoltaic Module Recycling Market 2020 Forecast to 2025

Original post:
Global Biochemistry Analysers Market 2020 Industry Analysis, Key Drivers, Business Strategy, Opportunities and Forecast to 2025 - Red & Black...

Biochemistry

Research On Global Biochemistry Analyzing Systems Market (impact of COVID-19) with Top Players: Roche,Siemens Healthcare,Abbott,Horiba Medical,EKF…

Global Biochemistry Analyzing Systems Market: Trends Estimates High Demand by 2027

The Biochemistry Analyzing Systems Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Biochemistry Analyzing Systems Industry Report is an in-depth study analyzing the current state of the Biochemistry Analyzing Systems Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Biochemistry Analyzing Systems Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Biochemistry Analyzing Systems market. All findings and data on the global Biochemistry Analyzing Systems market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Biochemistry Analyzing Systems market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Biochemistry Analyzing Systems industry.

Some of The Companies Competing in The Biochemistry Analyzing Systems Market are: Roche,Siemens Healthcare,Abbott,Horiba Medical,EKF Diagnostics,Randox Laboratories,Nihon Kohden Europe,Balio Diagnostics,Hitachi,Mindray Medical,Tianjin MNCHIP Technologies Co., Ltd.

Get a Sample Copy of the [emailprotected] https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-biochemistry-analyzing-systems-market-insights-and-forecast-to-2026?utm_source=dailyresearchchronicles&utm_medium=46

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Biochemistry Analyzing Systems Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and improvement plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Biochemistry Analyzing Systems Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Biochemistry Analyzing Systems market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Biochemistry Analyzing Systems market report answer pertaining to the regional reach of the industry?

The report claims to split the regional scope of the Biochemistry Analyzing Systems market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present how does the sales scenario look for the future?

Considering the present scenario, how much revenue will each region attain by the end of the forecast period?

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Biochemistry Analyzing Systems market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Biochemistry Analyzing Systems Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Biochemistry Analyzing Systems Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Biochemistry Analyzing Systems Market Effect Factors Analysis

Chapter 12: GlobalBiochemistry Analyzing Systems Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-biochemistry-analyzing-systems-market-insights-and-forecast-to-2026?utm_source=dailyresearchchronicles&utm_medium=46

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Continue reading here:
Research On Global Biochemistry Analyzing Systems Market (impact of COVID-19) with Top Players: Roche,Siemens Healthcare,Abbott,Horiba Medical,EKF...

Biochemistry

Sorting and secreting insulin by expiration date – Newswise

Newswise A study in the Journal of Biological Chemistry describes a new way to determine the age of insulin-storage parcels, known as granules, and sheds light on how their age affects their release into the bloodstream. The findings could help experts better understand diabetes and fine-tune therapies for it.

Insulin is a hormone that manages the level of sugar, or glucose, in the bloodstream. It is secreted by the pancreas into the bloodstream when blood sugar levels rise. When insulin circulates in the bloodstream, muscle and other cells absorb glucose to use it as fuel, and so blood sugar levels decline. In Type 2 diabetes, formerly known as adult-onset diabetes, this process fails. Glucose builds up in the blood, either because the pancreas cannot produce enough insulin to keep up with dietary sugar intake or because the gland simply isnt working as it should.

About one in 10 Americans and more than 415 million people worldwide have diabetes, according to the Centers for Disease Control and Prevention. Up to 95% of them have Type 2. Treatment often requires painful and frequent insulin injections or the use of mechanical insulin pumps. There is no cure.

The researchers noted in their paper that existing therapies for diabetes increase insulin secretion without regard for insulin granule age. Accordingly, they wrote, these approaches are effective only for a short period.

Insulin is produced by -cells of the pancreas and stored in insulin granules, which are then organized into pools and finally secreted into the bloodstream. Pools of young insulin granules are preferred for secretion over pools of old ones, for reasons that remain unclear.

The scientists whose work was published in JBC wanted to learn more about how pancreatic cells can distinguish between pools with young or old insulin granules.

Current therapeutics do not take the existence of pools into consideration, said Melkam Kebede, an assistant professor at the University of Sydney who oversaw the study. By evolution, the (pancreatic) cells have determined what to secrete and what not. Understanding the mechanism and molecular differences between the pools definitely is going to lead us into something meaningful.

In their paper, the researchers describe a technique they developed to distinguish younger insulin granules from older ones. The scientists placed a fluorescent protein, called Syncollin-dsRedE5TIMER, into newly created insulin granules and used a laser and detector to visualize that marker. In younger granules, the marker emits a green fluorescent light; as granules get older, the marker begins to emit a red fluorescence.

The authors monitored the movements of and other changes in insulin granule pools and saw that, as predicted, both mouse and human cells preferentially release younger insulin granule pools into the bloodstream in response to glucose.

The researchers then set out to learn more about how pancreatic cells sort insulin granules into pools and release them when they are experiencing metabolic stress. The concern is that, when under stress, -cells could potentially lose their ability to distinguish young (granules) from old, they wrote in their paper.

The team isolated -cells from mice and simulated chronic low, high and normal blood sugar levels and found different glucose levels determine which pools of insulin granules, young or old, are secreted. They saw similar results when they used a common mouse model for Type 2 diabetes known as the db/dbmouse.

These findings are important, Kebede said, because all the drugs that affect insulin secretionjust push any granule within the cell and eventually fail. Older insulin granules are naturally degraded in normally functioning beta cells, noted lead author Belinda Yau of the University of Sydney, but, in diabetes, a greater percentage of insulin granule pools are secreted, and theres a mismatch in how theyre released.

Being able to visualize insulin granules as they age and understanding better how their age affectstheir secretion may lead to the discovery of new biomarkerscapable of indicating the development of diabetes and could help in the creation of therapies for Type 2 diabetes.

If we can understand what makes up the granules and makes them do what they do, we can figure out a way to target the things that slow down or speed up their secretion, Yau said.

##

DOI: 10.1074/jbc.RA120.012432

This research was conducted by scientists at the University of Sidney, the University of Chicago the Garvan Institute of Medical Research in Australia, St. Vincent's Institute in Australia, and the Centre for Transplant and Renal Research at Westmead Hospital in Australia. The work was supported by the National Health and Medical Research Council (NHMRC) of Australia grant ID GNT1139828.

##

About theJournal of Biological Chemistry

JBCis a weekly peer-reviewed scientific journal that publishes research "motivated by biology, enabled by chemistry" across all areas of biochemistry and molecular biology. To read the latest research inJBC, visithttp://www.jbc.org/.

About the American Society for Biochemistry and Molecular Biology

The ASBMB is a nonprofit scientific and educational organization with more than 11,000 members worldwide. Most members teach and conduct research at colleges and universities. Others conduct research in government laboratories, at nonprofit research institutions and in industry. The Society publishes three journals: the Journal of Biological Chemistry, the Journal of Lipid Research, and Molecular and Cellular Proteomics. For more information about ASBMB, visitwww.asbmb.org.

Read this article:
Sorting and secreting insulin by expiration date - Newswise

Biochemistry

New Report Explored Global Carvacrol Market Demand Would Increase Rapidly by 2026 | COVID19 Impact Analysis | Key Players: SHUBH Flavour And…

The latest Carvacrolmarket report estimates the opportunities and current market scenario, providing insights and updates about the corresponding segments involved in the global Carvacrolmarket for the forecast period of 2020-2026. The report provides detailed assessment of key market dynamics and comprehensive information about the structure of the Carvacrolindustry. This market study contains exclusive insights into how the global Carvacrolmarket is predicted to grow during the forecast period.

The primary objective of the Carvacrol market report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with Carvacrol. This report also provides an estimation of the Carvacrolmarket size and corresponding revenue forecasts carried out in terms of US$. It also offers actionable insights based on the future trends in the Carvacrolmarket. Furthermore, new and emerging players in the global Carvacrolmarket can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global Carvacrolmarket.

Get Exclusive Sample copy on Carvacrol Market is available at https://inforgrowth.com/sample-request/6329485/carvacrol-market

The study is relevant for manufacturers, suppliers, distributors, and investors in the Carvacrolmarket. All stakeholders in the Carvacrolmarket, as well as industry experts, researchers, journalists, and business researchers can influence the information and data represented in the report.

Carvacrol Market 2020-2026: Segmentation

The Carvacrol market report covers major market players like SHUBH Flavour And Fragrances Pvt., Foreverest Resources Ltd, Weifang Union Biochemistry, Anhui Haibei Import & Export Co., Hairui Natural Plant Co., High Hope Intl Group, Jiangxi Baicao Pharmaceutical, Shree Bankey Behari Lal Aromatics, Fuzhou Farwell Import & Export Co., Kunshan Sainty Y.J.Y. Co., Xian Aladdin Biological Technology,

Carvacrol Market is segmented as below:

By Product Type: Natural Type, Synthetic Type,

Breakup by Application:Flavors and Fragrances, Food Additives, Pharmaceutical Intermediates, Other

Impact of COVID-19:CarvacrolMarket report analyses the impact of Coronavirus (COVID-19) on the Carvacrolindustry.Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Carvacrolmarket in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Download the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6329485/carvacrol-market

Global Carvacrol Market Report Answers Below Queries:

To know about the global trends impacting the future of market research, contact at: https://inforgrowth.com/enquiry/6329485/carvacrol-market

Key Questions Answered in this Report:

What is the market size of the Carvacrol industry?This report covers the historical market size of the industry (2013-2019), and forecasts for 2020 and the next 5 years. Market size includes the total revenues of companies.

What is the outlook for the Carvacrol industry?This report has over a dozen market forecasts (2020 and the next 5 years) on the industry, including total sales, a number of companies, attractive investment opportunities, operating expenses, and others.

What industry analysis/data exists for the Carvacrol industry?This report covers key segments and sub-segments, key drivers, restraints, opportunities and challenges in the market and how they are expected to impact the Carvacrol industry. Take a look at the table of contents below to see the scope of analysis and data on the industry.

How many companies are in the Carvacrol industry?This report analyzes the historical and forecasted number of companies, locations in the industry, and breaks them down by company size over time. The report also provides company rank against its competitors with respect to revenue, profit comparison, operational efficiency, cost competitiveness, and market capitalization.

What are the financial metrics for the industry?This report covers many financial metrics for the industry including profitability, Market value- chain and key trends impacting every node with reference to companys growth, revenue, return on sales, etc.

What are the most important benchmarks for the Carvacrol industry?Some of the most important benchmarks for the industry include sales growth, productivity (revenue), operating expense breakdown, the span of control, organizational make-up. All of which youll find in this market report.

Get Special Discount UP TO 50% for this Report:https://inforgrowth.com/discount/6329485/carvacrol-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: US: +1-909-329-2808UK: +44 (203) 743 1898

Read more here:
New Report Explored Global Carvacrol Market Demand Would Increase Rapidly by 2026 | COVID19 Impact Analysis | Key Players: SHUBH Flavour And...

Embryology

Artificial intelligence in embryo selection: a reality thanks to IVIRMA Global – PRNewswire

VALENCIA, Spain, July 6,2020 /PRNewswire/ --As spectacular and futuristic as it may seem, using Artificial Intelligence to automatically analyze embryos in a standardized way to improve pregnancy rates is already a reality. This is confirmed by an IVIRMA Global study entitled 'A universal algorithm is available in last generation time-lapse incubators: embryo score provided by the KIDScoreD5 is strongly correlated with chromosomal status and clinical outcomes'.

IVIRMA Global has already participated in the development of the EmbryoScope (incubator with time-lapse technology) from its beginnings, helping in its evolution and laying the foundations for automatic embryo selection. In its latest development, EmbryoScope presents its newest software system, KIDScoreD5, which automatically performs embryo selection and classification.

The study has been carried out over the last three years and has become the most extensive case study in the history of embryology to date (more than 20,000 embryos and more than 3,000 patients have been analyzed). In the study, IVIRMA Global has demonstrated that universal, standardized and automatic embryo selection is a reality for the field of embryology. As the study's principal researcher, Dr. Marcos Meseguer, scientific supervisor of IVI Valencia, comments, "The KIDScoreD5 system automatically classifies embryos using Artificial Intelligence, it detects and evaluates all the steps in the development of the embryo and also classifies its morphology".

Dr. Meseguer points out that, "We have seen that the KIDScoreD5 system makes an assessment to distinguish between those embryos that are more likely to be chromosomally normal, called euploid embryos, and those that are not, called aneuploid embryos." Based on the score the system gives each embryo, we know its probability of gestation and the possibility of taking a healthy baby home.

The KIDScoreD5 system analyzes the embryos automatically classifying them from one to ten depending on their quality and morphology. Since automated embryo selection is more accurate than manual selection, the probability of a successful pregnancy is directly linked to the percentage score and, therefore, the patient has a greater chance of success.

Main values of the study and the KIDScoreD5 system

About IVIRMA Global

IVI was founded in 1990, as the first medical institution in Spain fully dedicated to assisted reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest technologies. In early 2017, IVI merged with RMANJ, becoming the largest assisted reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for reproductive medicine. http://www.ivi.es- http://www.rmanetwork.com.

For more information:

SOURCE IVIRMA Global

Home

See the rest here:
Artificial intelligence in embryo selection: a reality thanks to IVIRMA Global - PRNewswire

Embryology

Breakthrough study demonstrates the ‘re-awakening’ of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -…

LONDON, July 6, 2020 /PRNewswire/ -- IVIRMA, a global network of fertility clinics and world-leading pioneer in fertility research, are presenting a breakthrough study at the 36th Congress of the European Society of Human Reproduction and Embryology (ESHRE) today, demonstrating the possibility of 're-awakening' the ovaries in women under 40 (38 years and below) with the lowest reproductive reserve at the ovarian level.1 The ASCOT technique (involving infusion of stem cells in the ovarian artery), which has recently been shown to be successful in low-responder patients, has now shown it can achieve pregnancy in a woman with premature ovarian failure (POF).1

The study, 'Bone marrow derived stem cells restore ovarian function and fertility in premature ovarian insufficiency women. Interim report of a randomized trial: mobilization versus ovarian injection',1 which is still ongoing, includes two study arms: one using the ASCOT technique, that is, the infusion of stem cells in the ovarian artery* and, second, a less invasive option consisting of mobilising the stem cells, and allowing them to reach the ovaries through the bloodstream directly. The preliminary results have shown that ovarian follicle development was achieved in both groups, with some patients re-starting menstruation, and a decrease in menopausal symptoms. As a result of this procedure, embryos were obtained in 2 out of the 10 participants, and even one pregnancy through the ASCOT technique was achieved.

Dr. Diaz, Medical Director, IVI London, a leading fertility specialist and co-pioneer of the world's first womb transplant, commented, "We are truly excited by these very promising results achieving ovary re-awakening and pregnancy using stem cells in a woman who previously may not have had the option to conceive using her own eggs. We continually strive to pioneer on the cutting-edge of fertility research, as we know how harrowing it can be for every person struggling to conceive. These new techniques may give us potential new options for women with premature ovarian failure, in addition to those with low ovarian reserve."

It is estimated that 1 in 100 women under 40 years of age suffer from premature ovarian failure (POF) in the UK. 2.5% of all patients with POF are adolescents.2 This premature cessation of ovarian activity is one of the most challenging scenarios in terms of reproduction and can be devastating. Now, thanks to the findings of this study, led by Dr. Sonia Herraiz, researcher at the IVI Foundation-IIS la Fe, Spain and Dr. Nuria Pellicer, gynaecologist at Hospital la Fe in Valencia, Spain, there might be hope for women suffering from this fertility issue.

Dr. Nuria Pellicer, Gynaecologist, Hospital la Fe, Valencia, Spain added, "So far, we obtained embryos in 2 of the 10 patients included and one 37-week pregnancy in the ASCOT arm, in patients with almost no chance of successful pregnancy with classic in vitro fertilisation procedures. We found that both arms promoted the development of follicles, and some patients have even recovered their menstruation, thus reducing menopausal symptoms However, these are preliminary results of an ongoing study, so we remain cautious until the study is complete. We aim to develop a technique that is as minimally invasive as possible over time and standardise it so that it can be implemented in all our clinics. We would like to make it possible to offer any woman who wishes to become a mother the possibility of doing so, even when her reproductive circumstances are unfavourable."

"This is a very encouraging line of research in which we will continue to work with a single goal: to improve assisted reproduction techniques and treatments in order to obtain the best results, however difficult the reproductive prognosis may seem," concluded Dr. Herraiz, researcher at the IVI Foundation-IIS, la Fe, Spain.

More About the Study1

In addition to this research, IVI are presenting three more studies at the ESHRE Congress:

These new techniques and other research conducted by IVI is translated and applied to the treatments available in their clinics across the world, which is in turn reflected in the achieved results. The London clinic has achieved 71.4% clinical pregnancy rates per embryos transferred in women under the age of 386 and recent data shows that with PGT-A genetic screening the evolutive pregnancy rate is 57% in women undergoing treatment at IVI London as compared to the national average of 42%.7 Furthermore, 100% of these pregnancies have been achieved through single embryo transfer, eliminating chances of multiple pregnancy and the complications that arise with it.7

More about the ASCOT technique development: 3 babies and 6 pregnancies achieved so far in low-responder patients

To date, 3 babies and 6 pregnancies have been achieved using the ASCOT technique for ovarian rejuvenation in low-responder patients with low ovarian reserve, pioneered by IVIRMA Global. The technique involves transplanting bone marrow-derived stem cells (BMDSC) into the ovarian artery, achieving a partial reversal of ageing of the ovary, the organ responsible for ovulation, and activating the dormant follicles that would otherwise remain arrested in the ovary. After its first phase in animal models to test the effectiveness of the technique with stem cells, this study went to its second phase in low-responder patients. A total of 20 patients had their stem cells mobilized, extracted from peripheral blood and implanted back into the ovary in order to reverse the ageing process and activate the dormant follicles. This technique has improved ovarian function biomarkers in 81% of low responder patients. In addition, spontaneous pregnancies occurred. In view of the success of this phase, the next stage was undertaken, which consisted of recruiting women under 38 years of age, this time with early ovarian failure (a situation with a worse reproductive prognosis that of low responders). From here the above-mentioned study arose.

IVIRMA Global and IVI London, UK

IVI was founded in 1990, as the first medical institution in Spain fully dedicated to Assisted Reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest Assisted Reproduction technologies. In early 2017, IVI merged with RMANJ, becoming the largest Assisted Reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for Reproductive Medicine. In 2016 IVI opened its doors in London, located in the heart of the medical district.www.rmanetwork.comhttps://ivi-fertility.co.uk/

References

Logo - https://mma.prnewswire.com/media/1200377/IVI_Logo.jpg

Read the rest here:
Breakthrough study demonstrates the 're-awakening' of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -...

Embryology

Adelaide fertility software launches in the UK, Europe – InDaily

adelaide Monday July 06, 2020

An Adelaide-based company that uses artificial intelligence to increase the chance of pregnancy through IVF has launched its software application in the UK and Europe.

Life Whisperer, the fertility arm of AI healthcare company Presagen, commercialised its flagship product in Australia in late January and released it through a distributor into India, Sri Lanka and Bangladesh last month.

Approvals are also being sought to sell the software tool in Japan, Southeast Asia and the US, where it has conducted a number of clinical trials.

Last weeks launch into the UK and Europe is a major step in the three-and-a-half-year journey for the product, which was forced into a COVID-19 hiatus from March to May when many of the worlds fertility clinics closed their doors.

Get InDaily in your inbox. Daily. The best local news every workday at lunch time.

Thanks for signing up to the InDaily newsletter.

Presagen currently has 15 staff and small offices in San Francisco and London to drive the global expansion.

Founder and CEO Dr Michelle Perugini said the company had strong connections in the UK and Europe and a number of clinics were already trialling the product in the region.

She said getting clinics on board as commercial customers was the next stage.

Regulatory approval in the UK and Europe represents a significant opportunity for Life Whisperer to expand its global presence, and we are very much looking forward to working with clinics and patients across the region, supported from our London Offices, she said.

Its a secure web-based application that is completely scalable so we can set up new clinics within minutes anywhere in the world.

Life Whisperer co-founders Dr Jonathan Hall (left), Dr Michelle Perugini and Dr Don Perugini. Picture: Matt Loxton.

The Embryo Viability Application for IVF clinics uses artificial intelligence to analyse images of embryos to assist clinicians to identify which embryo will likely lead to a pregnancy.

By selecting the best embryo, Life Whisperer aims to shorten the time to pregnancy and improve outcomes for couples undergoing IVF treatment.

An international study recently published in the journal Human Reproduction involved blind evaluation of 1600 IVF embryos.

Life Whisperer was shown to perform 25 per cent better than traditional manual methods of embryo assessment by highly experienced embryologists.

The technology will be showcased on Tuesday night Australian time at the 36th Annual Meeting of the European Society of Human Reproduction and Embryology, which is being held online this year.

Internationally renowned fertility expert Matthew (Tex) VerMilyea from Ovation Fertility (USA) will present Life Whisperers latest advances in AI for IVF at the event where Presagen will also have a virtual exhibition booth .

Dr Perugini said Presagen was planning a significant capital raise this year to drive growth.

She said the company was looking forward to working with IVF clinics across the globe to offer Life Whisperer to patients at a low cost, meaning more couples could gain more certainty in embryo selection and achieve success sooner, with fewer IVF cycles.

Life Whisperer is poised to become the global gold standard embryo pre-screening tool in IVF, supporting the clinical decision about which embryo is most viable.

Dr Perugini and Presagen CTO Dr Jonathan Hall are both past winners of InDailys 40 Under 40 Awards, which recognises South Australias top business leaders aged under 40.

Nominations are still openfor this years 40 Under 40 Awards with judging to commence in August before the awards are held in October.

In times like these InDaily provides valuable, local independent journalism in South Australia. As a news organisation it offers an alternative to The Advertiser, a different voice and a closer look at what is happening in our city and state for free. Any contribution to help fund our work is appreciated. Please click below to donate to InDaily.

Powered by PressPatron

Original post:
Adelaide fertility software launches in the UK, Europe - InDaily

Embryology

HFEA publishes 2018 trends in fertility treatment – BioNews

6 July 2020

The Human Fertility and Embryology Authority (HFEA)has published its latest analysis on trends in fertility treatment, based on data from across the UK in 2018.

Headline findings include an increase in IVFsuccess rates, a surge in eggand embryofreezing, and a decrease in NHSfunding for fertility treatments.

Sally Cheshire, chair of the HFEA, said: 'While fertility treatment is never a guarantee for a baby, we are pleased to see that birth rates have increased over the years and the average birth rate is now steady at 23 percent. Whilst this leaves many couples without their longed-for family after treatment, these small year-on-year increases are important for the sector to build on.'

In 2018 about 54,000 patients underwent 68,724 fresh and frozen IVFcycles and 5,651 donor insemination cycles at HFEA licensed fertility clinics across the UK. IVF birth rates increased for all patient groups under the age of 43 over time. Patients below the age of 35 had a birth rate of 31 percent per transferred embryo (23 percent for all patients), an increase from only nine percent in 1991, when HFEA was established.

Age remains a key factor for IVF success, with a birth rate below five percent for women over 43 who use their own eggs.

Multiple pregnancy, one of the main risk factors of IVF, has for the first time fallen to eight percent, as it has become clear that implanting more than one embryo has no significant impact on the chance of live birth.

The report also states that the number of patients choosing embryo and egg storage cycles increased five-fold from 1400 in 2013 to 9000 in 2018. The number of women freezing unfertilisedeggs has also climbed from 569 in 2013 to 2000 in 2018. Frozen embryo transfers are now more successful than fresh ones, although only by a small margin.

Sarah Norcross from the Progress Educational Trust said: 'The women we have spoken to value motherhood and having a family is really important to them and so they are choosing to freeze their eggs as a back-up plan in case they need them in the future. Of course, they may not need them as they may find a partner and get pregnant the old-fashioned way. I think there is a greater awareness of egg freezing as a reproductive choice and also of the biological clock and so women are choosing to invest money in trying to improve their reproductive options'.

The level of NHS funding for fertility treatment varies across the UK: In Scotland, 60 percent of fertility treatments are funded by the NHS, but in England where funding is controlled locally by clinical commission groups (CCGs), this figure has fallen below 30 percent in some areas.

'What is hugely disappointing is the continued fall in NHS-funded cycles... Whilst the Nice [National Institute forHealthand Care Excellence] guidance states that all eligible couples should be entitled to three full cycles (including the use of frozen embryos)' said Professor Adam Balen, the Royal College of Obstetricians and Gynaecologists spokesperson on reproductive medicine. 'IVF is cost effective and has shown to be an economic benefit to society.'

Read more here:
HFEA publishes 2018 trends in fertility treatment - BioNews

Immunology

Immunity to the coronavirus is ‘fragile’ and ‘short lived,’ immunologist warns – CNBC

It is not a "safe bet" to rely on immunity to Covid-19 as a strategy for coping with the pandemic, one expert has warned, adding that herd immunity strategies were "probably never going to work."

Speaking to CNBC's "Squawk Box Europe" on Monday, Danny Altmann, professor of immunology at Imperial College London, said that in towns and cities where there had been coronavirus infections, only 10% to 15% of the population was likely to be immune.

"And immunity to this thing looks rather fragile it looks like some people might have antibodies for a few months and then it might wane, so it's not looking like a safe bet," he said. "It's a very deceitful virus and immunity to it is very confusing and rather short lived."

He also raised questions about the likely success of so-called herd immunity when a population is allowed some exposure to the virus in order to buildimmunity among the general population which has been cited by health officials in Sweden, which controversially avoided a lockdown.

Despite a global race to find a vaccine for the coronavirus, experts remain uncertain about whether the antibodies present in people who have had the virus actually provide immunity to reinfection.

Top White House health advisor Dr. Anthony Fauci speculated last month that if Covid-19 behaved like other coronaviruses, there "likely isn't going to be a long duration of immunity" from antibodies or a vaccine. Meanwhile, the WHO has stated that it remains unclear whether those who have already caught the virus once will be immune to getting it again.

Imperial College London's Altmann said on Monday that he was expecting a second wave of Covid-19, and that although governments were much better prepared for a resurgence in infections, the situation remained "very, very scary."

"Anybody who thinks that it has got more mild or gone away or that somehow the problem's going to solve itself is kidding themselves," he told CNBC. "It's still a very lethal virus, it still infects people very, very readily. And I think humanity isn't used to dealing with those realities."

He also emphasized that it was difficult to make predictions about if or when an effective vaccine for Covid-19 might be identified.

"The devil is in the detail, vaccines aren't that easy," Altmann said. "There's more than 100 in trial at the moment and many things can go wrong along the way. I place no bets at the moment myself."

David King, former chief scientific adviser to the U.K. government, warned in an interview with Sky News on Sunday that the U.K. would have an additional 27,000 deaths from Covid-19 if it stayed on its current trajectory. To date, 44,305 people have died from Covid-19 in the U.K., according to data compiled by Johns Hopkins University.

Altmann told CNBC that he agreed with this projection "to some extent," claiming that a lot of scientists, immunologists and vaccine experts still felt "very scared" about the pandemic.

He acknowledged that policymakers needed to find a balance between protecting public health and preventing socioeconomic disasters, but added: "We need to continue to be led by the science and the medicine and do the right thing. And doing the right thing means everything you can do to block transmission."

The new strain of coronavirus, first reported to the WHO in late December, has infected more than 11.4 million people and killed 534,825 globally to date, according to data compiled by Johns Hopkins University.

Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, warned last week that the pandemic was accelerating around the world as economies began to reopen.

View original post here:
Immunity to the coronavirus is 'fragile' and 'short lived,' immunologist warns - CNBC